Metsera reports positive Phase 2b data: MET-097i weight loss up to 14.1%, tolerability favorable

Metsera, Inc.

Placebo-subtracted mean weight loss up to 14.1% after 28 weeks in VESPER-1; no plateau observed.
Class-leading tolerability: minimal diarrhea, nausea risk difference 13%, vomiting 11% at highest dose with two-step titration.
Only 2.9% study discontinuation in VESPER-1; high retention across both trials.
Phase 3 program to start late 2025; VESPER-2 (T2DM) data expected early 2026, VESPER-3 monthly dosing data by year-end 2025.
MET-097i serves as backbone for four additional programs: monthly NuSH combination, GIP combo, oral, quarterly prodrug.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.